Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status.

Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status.

<h4>Introduction</h4>Although cetuximab and panitumumab show an increased efficacy for patients with KRAS-NRAS-BRAF and PI3KCA wild-type metastatic colorectal cancer, primary resistance occurs in a relevant subset of molecularly enriched populations.<h4>Patients and methods</h4&...

Full description

Saved in:
Bibliographic Details
Main Authors: Filippo Pietrantonio, Claudia Maggi, Maria Di Bartolomeo, Maria Grazia Facciorusso, Federica Perrone, Adele Testi, Roberto Iacovelli, Rosalba Miceli, Ilaria Bossi, Giorgia Leone, Massimo Milione, Giuseppe Pelosi, Filippo de Braud
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0092147&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items